Posted by Michael Wonder on 11 Feb 2022
The Government could force a price cut for this prostate cancer drug by as much as 80%. Why hasn’t it acted?
10 February 2022 - Xtandi, a wonder drug for prostate cancer, was developed at UCLA with substantial funding from the taxpayers through the Pentagon and the National Institutes of Health.
UCLA has profited handsomely from the drug, to the tune of more than $520 million in royalties. The drug companies that acquired the manufacturing license, including Pfizer and the Tokyo firm Astellas, have also raked in billions in sales.
